He goes into the mechanism of action of immunotherapy and why it could work well in bladder cancer.
Where do we currently stand with the use of immunotherapy in the NEOADJUVANT setting of muscle-invasive bladder cancer? And what is currently the best place to integrate immunotherapy for METASTATIC bladder cancer?
Dr. Cathomas closes with the answer to the question of why some patients benefit much more than others from immunotherapy.
Dr. Richard Cathomas is an oncologist panel member on the EAU Guidelines for muscle-invasive bladder cancer.
For more EAU podcasts, please go to your favourite podcast app and subscribe to our EAU podcast channel for regular updates.
Contact our organiser